All
From Overwhelmed to Empowered: Pluvicto is Changing Metastatic Prostate Cancer Care
July 30th 2025Navigating a metastatic castration-resistant prostate cancer (mCRPC) diagnosis while preserving self-identity can feel like wandering through a foggy wilderness, quiet and cautious, afraid that any sound might reveal vulnerability. When forced to rethink the direction of life and navigate the various treatment options available while bearing the emotional toll of the unknown, it would be understandable to feel overwhelmed. Knowing there’s a clear next step can offer hope, a reason to speak up, and a renewed sense of control. For many, that step could be Pluvicto® (lutetium Lu 177 vipivotide tetraxetan).